Latest Juvenile Diabetes Research Foundation Stories
Vishal Bhagat was a former student at the University of Texas and suffered from juvenile diabetes. A cause near to his heart, Vishal understood diabetes affects millions of children around the world. In effort to help find a cure, he pioneered the "Sugar-Free Bowl," a charity flag football tournament that benefits the Juvenile Diabetes Research Foundation. Sadly, Vishal's life was cut short by a tragic drowning accident. Now in its third year, family and friends established "Clubs for Cure"...
Research and Markets (http://www.researchandmarkets.com/research/06345f/diabetics_attitud) has announced the addition of the "Diabetics: Attitudes and Behaviors in the United States 2008" report to their offering. Diabetes is a highly complex disease that entails a range of screening methods, treatment, monitoring, and management. Comprised of pre-diabetes, Type 1 (an autoimmune disease) and Type 2 (a metabolic disorder), diabetes affects 23.6 million people in the U.S., with another 57...
A U.S. study has determined type 1 diabetes patients using continuous glucose monitoring improved their HbA1c blood sugar control levels. The Juvenile Diabetes Research Foundation International-funded trial showed type 1 diabetes patients using continuous glucose monitoring, or CGM, devices experienced significant improvements in HbA1c blood sugar control. HbA1c is a form of hemoglobin that's used to identify the average plasma glucose concentration in a patient's blood during prolonged...
New study data presented by the Juvenile Diabetes Research Foundation (JDRF) today at the 44th annual meeting of the European Association for the Study of Diabetes (EASD), showed the use of Continuous Glucose Monitoring (CGM) to be effective in the management of Type 1 Diabetes. The JDRF initiated the study to help increase access to and reimbursement of this new technology, which has been heralded as one of the most significant advancements in diabetes self-management in the past decade....
Results of the largest ever Continuous Glucose Monitoring (CGM) study were published online today by the New England Journal of Medicine. The study demonstrated that Personal CGM therapy significantly reduced the average blood glucose levels (A1c) of adult patients with type 1 diabetes, validating the growing body of clinical evidence in support of Personal CGM therapy and its ability to substantially improve diabetes management and glucose control. Studies have shown that reducing A1c can...
BURGESS HILL, England, September 1 /PRNewswire-FirstCall/ -- With some 20,000 UK children with Type 1 diabetes(i) about to start the new school year, new guidance from the National Institute for Health and Clinical Excellence (NICE) looks set to revolutionise the way children manage their diabetes, granting more freedom and control for their condition, by greater access to insulin pump therapy. The new recommendations finally acknowledge key research(ii) supported by Roche, that shows the...
Scientists at the Stanford University School of Medicine are shedding light on how type-1 diabetes begins. Doctors have known the disease is caused by an autoimmune attack on the pancreas, but the exact trigger of the attack has been unclear. Now, a new study in mice implicates the immune signal interferon-alpha as an early culprit in a chain of events that upend sugar metabolism and make patients dependent on lifelong insulin injections. "We never considered that interferon-alpha could...
By Stories by MADONNA YANCEY, Courier & Press correspondent Childhood should be a time filled with fun and promise. Not a time of worry and constant medical concerns. For Dana Lobel the wonder of childhood dimmed when her 10-year- old son, Ben, was diagnosed with type 1 diabetes. "It changes your lives completely," Dana Lobel said. "You lose a lot of spontaneity with this disease. Anything your child does can affect his blood sugar. Managing the disease is a lot of responsibility for a...
EpiVax, Inc, a leader in the field of computational immunology, announced today that it has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH), to develop "Epi-13", a novel therapeutic for the prevention and treatment of Type 1 diabetes, a devastating and chronic autoimmune disease that affects three million Americans. NIDDK will provide EpiVax $600,000 over two years to reach...
INDIANAPOLIS, June 27 /PRNewswire-FirstCall/ -- Media conference call with Gary Hall Jr.: Monday, June 30, 2:00 PM EDT United States: (800) 553-0327 International: +1 (612) 332-0226 When Olympian Gary Hall Jr. was diagnosed with diabetes, his physician prescribed Eli Lilly and Company's fast-acting insulin Humalog(R) (insulin lispro injection [rDNA origin]) to help manage his blood sugar and keep alive his gold-medal dreams -- hopes he fulfilled in the 2000 Sydney Games and...
